Compare J B Hunt Transport Services Inc (JBHT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs McKesson Corporation — how do they compare? J B Hunt Transport Services Inc trades at $229 (market cap $21.45B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 5.1× J B Hunt Transport Services Inc's market cap, and J B Hunt Transport Services Inc pays the higher dividend (0.79%). Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and McKesson Corporation for 74 Days on average.
| JBHT | MCK | |
|---|---|---|
Market Cap | $21.45B | $108.46B |
Volume | 1,028,680 | 712,607 |
Sector | Industrials | Health |
52-Week High | $298.41 | $995.69 |
52-Week Low | $137.09 | $725.17 |
Typical Hold Time | 45 Days | 74 Days |
Enterprise Value | $22.59B | $115.00B |
Dividend Yield | 0.79% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $222.64, down 1.46% on the day, amid a bearish technical signal and ongoing securities class action investigations. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected October 15, 2026. Fundamentals show a P/E of 31.67, net income margin of 5.31%, and strong cash flow from operations of $1.68 billion in 2025. Analyst consensus remains bullish with a $289.40 price target, though rising costs and legal scrutiny present headwinds.
The outlook is mixed; strong freight demand and earnings beats support upside potential, but near-term pressure from fuel costs and legal overhangs may limit gains. The stock offers value if operational efficiency improves, yet investors face risks from volatile diesel prices and potential litigation outcomes. The upcoming Q3 earnings will be critical for confirming the company's ability to navigate cost pressures.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
